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With great interest we have read the article of Hoorntje
et al. [1] addressing the usefulness of stereotactic large-
core needle biopsy prior to surgery in BI-RADS 5 le-
sions. We fully agree with the authors that the far
majority of women with BI-RADS 5 lesions presenting
as non-calciﬁed mass densities will not need stereotactic
large core needle biopsy. However, we do not agree with
the authors’ suggestions of immediate surgery with
sentinel node biopsy in case of BI-RADS 5 lesions
presenting as a density without calciﬁcations.
International guidelines state that at least 90% of
women with breast cancer should have a pre-operative
diagnosis of malignancy (ﬁne needle biopsy or core
biopsy reported as deﬁnitely malignant) [2]. Pre-oper-
ative histological diagnosis allows planning of deﬁnite
treatment, i.e. surgery aiming for negative margins,
sentinel lymph node biopsy or axillary lymph node
dissection and in some cases neoadjuvant chemother-
apy. In addition, pre-operative histology may diminish
the patient’s uncertainty and gives the treating physi-
cian the possibility to provide the necessary informa-
tion concerning the disease and its treatment. We think
that today, every woman with an abnormal mam-
mography should receive a deﬁnitive diagnosis without
delay, in any case before admission to surgery (which
might take weeks, particularly in countries with long
waiting lists).
Does that mean that all women with BI-RADS 5
lesions presenting as mass densities should undergo
stereotactic large core needle biopsy? Probably anyone
will agree that the answer is no. The far majority of
mammographic densities can be targeted by the more
convenient and less expensive ultrasound guided large-
core needle biopsy.
In addition, we ﬁnd the calculation at the end of the
results section somewhat diﬃcult to follow. The authors
state that ‘scenario II’ (immediate surgery with sentinel
lymph node biopsy for BI-RADS 5 lesions presenting as
mass densities) could prevent 65% (i.e. 154 out of 238)
of the stereotactic large core needle biopsies. We believe
that this ﬁgure is largely overestimated. In the discussion
section, the authors say that in case of planned mas-
tectomy, pre-operative stereotactic large-core needle
biopsy is indicated. In this study, 32% of the patients
had mastectomy as primary surgical intervention. Sub-
sequently, one third (± 51) of the 154 ‘preventable’
stereotactic large core needle biopsies would not be so
‘preventable’ after all. A preventable proportion of 43%
(103 out of 238) stereotactic large-core needle biopsies
would be more realistic. Multifocality or occurrence of
lesions otherwise not suitable for sentinel lymph node
biopsy could even lower this number.
One might conclude that the prevention of some 100
preoperative biopsies (ultrasound or stereotactic guided)
makes up for four unnecessarily over-treated benign
lesions. However, when taking into account the delay in
providing an anxious patient with a deﬁnite diagnosis
and information concerning her disease, we’re not so
sure if the balance still favours ‘scenario II’.
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